netFormulary NHS
South Staffordshire Joint Formulary
Cannock Chase Clinical Commissioning Group
East Staffordshire Clinical Commissioning Group
South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group
Stafford and Surrounds Clinical Commissioning Group
 Search
 Formulary Chapter 13: Skin - Full Chapter
Chapter Links...
 Details...
13.08.01  Expand sub section  Sunscreen preparations
13.08.01  Expand sub section  Photodamage
Diclofenac 3% gel (Solaraze)
(Prescribe by brand to avoid confusion)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
Diclofenac 3% gel (Solaraze gel ) Actinic Keratosis- For treatement of superficial lesions in mild disease

Prescribe by Brand
 
   
Cytotoxic Drug Fluorouracil (Efudix)
(Efudix)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber
Superficial malignant and pre-malignant skin lesions.
Initiation by Dermatologist 
   
Cytotoxic Drug Actikerall
(Fluorouracil and Salicylic Acid)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
Superficial malignant and pre-malignant skin lesions.
 
   
Ingenol mebutateBlack Triangle (Picato)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red

MHRA advice (Oct 2019): Ingenol mebutate gel (Picato▼)- increased incidence of skin tumours seen in some clinical studies

MHRA advice (Feb 2020): Ingenol mebutate gel (Picato▼): suspension of the licence due to risk of skin malignancy. Clinicians should stop prescribing Picato and consider other treatment options for actinic keratosis as appropriate. The licence of ingenol mebutate (Picato) has been suspended as a precautionary measure while the European Medicines Agency (EMA) continues to investigate concerns about a possible increased risk of skin malignancy.

 
Link  FDA warning of severe allergic reactions and herpes zoster (shingles)associated with use of picato gel (08.01.15)
   
 ....
 Non Formulary Items
Methyl-5-Aminolevulinate  (Metvix)

View adult BNF View SPC online View childrens BNF
Non Formulary
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Drugs which require special consideration. These are drugs for Consultant Prescribing ONLY. They should not be prescribed in Primary Care.  

Amber

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care. For some drugs there may be a Ricad in place to aid the transition to primary care.  

Amber E

Drugs that should be initiated by a Specialist but are suitable for continuation in Primary Care but also require and ESCA (Shared Care Agreement)   

Green

Suitable first-line drugs for implementation in Primary Care  

On Formulary

South Staffs Formulary Choice  

netFormulary